Articles tagged "Kidney transplantation"

2016 American Transplant Congress
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.
K. Sablik,¹ C. Looman,² M. Clahsen-van Groningen,³ J. Damman,³ D. Roelen,⁴ M. van Agteren,¹ M. Betjes.¹
¹Nephrology and Transplantation, Erasmus MC University Center, Rotterdam, Netherlands; ²Biostatistics, Erasmus MC University Center, Rotterdam, Netherlands; ³Pathology, Erasmus MC University Center, Rotterdam, Netherlands; ⁴Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Introduction Transplant glomerulopathy (TG) is commonly associated with chronic antibody mediated rejection and is a major cause of late kidney allograft loss with no established…
2016 American Transplant Congress
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
R. Bray,¹ R. Parsons,² N. Turgeon,² H. Gebel.¹
¹Pathology, Emory University, Atlanta, GA; ²Emory Transplant Center, Emory University, Atlanta, GA.
AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…
2016 American Transplant Congress
Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies.
F. Tinney Jr,¹ L. Yessayan,² M. Abouljoud,³ A. Patel.³
¹Wayne State University School of Medicine, Detroit, MI; ²Department of Nephrology, Henry Ford Hospital, Detroit, MI; ³Transplant Institute, Henry Ford Hospital, Detroit, MI.
INTRODUCTION: Nephrosclerosis is often associated with pathological injury to kidneys resulting from chronic high blood pressure and/or aging, and may predict the progression of decline…
2016 American Transplant Congress
An Assurance of Insurance: Should Living Kidney Donors Be Required to Have Health Insurance?
J. Siegel,¹ A. Humar,² P. Gianaros,¹ J. Steel.²
¹Department of Psychology, University of Pittsburgh, Pittsburgh, PA; ²Department of Surgery, Division of Transplantation, University of Pittsburgh, Pittsburgh, PA.
Lack of health insurance has been related lack of access to health care, poorer health, and increased mortality. In this study, we investigate sociodemographic predictors…
2016 American Transplant Congress
Deceased Donor ABO-Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity.
M. Manook,¹ L. Bradbury,² D. Osei-Bordom,¹ B. Sandhu,¹ T. Maggs,¹ O. Shaw,¹ N. Kessaris,¹ S. Shah,³ A. Dorling, N. Mamode.¹
¹Guy's & St Thomas' Hospital, London, United Kingdom; ²NHS Blood & Transplant, Bristol, United Kingdom; ³King's College Hospital, London, United Kingdom.
Introduction: Patients with blood group O or B wait significantly longer for a kidney transplant than other groups. Blood group incompatible transplantation is widely accepted…
2016 American Transplant Congress
Early Hospital Readmisison Among Older Kideny Transplant Recipients.
E. King, L. Kucirka, M. McAdams-DeMarco, F. Al-Ammary, D. Segev.
Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.
BACKGROUND: We previously established 31% of all kidney transplant (KT) recipients experience early hospital readmission (EHR). We hypothesized that rates of EHR might be higher…
2016 American Transplant Congress
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
J. Chen,¹ R. Hoffman,² M. Thomas,² J. Gervasio.²
¹IU Health, University Hospital, Indianapolis, IN; ²Butler University, Indianapolis, IN.
Valganciclovir is the preferred prophylactic therapy for the prevention of CMV in transplant recipients and is the most expensive medication required post transplantation. The objective…
2016 American Transplant Congress
The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.
F. Eskandary,^1,2 J. Reeve,^1,3 H. Regele,⁴ L. Hidalgo,^1,3 D. Yoo,¹ N. Kozakowski,⁴ K. Famulski,¹ G. Böhmig,² P. Halloran.^1,5
¹Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada; ²Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁴Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria; ⁵Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, AB, Canada.
Study purpose: ABMR is a driving force of long-term allograft loss in organ transplantation. The present study was designed to characterize the phenotypic diversity of…
2016 American Transplant Congress
Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.
R. Crew, S. Patel, H. Morris, M. Chiles, L. Ratner.
Columbia University, New York.
INTRO: Progress in AMR treatment has improved early graft survival. Since the new kidney allocation system results in more sensitized patients getting transplanted, we expect…
2016 American Transplant Congress
The Epidemiology of Clostridium difficile Infection in a National Kidney Transplant Center.
C. Kennedy,¹ C. Waldron,¹ M. Scally,² K. Burns,² C. Magee,¹ F. Fitzpatrick.²
¹Department of Nephrology, Beaumont Hospital, Dublin, Ireland; ²Department of Microbiology, Beaumont Hospital, Dublin, Ireland.
BackgroundKidney transplant recipients (KTRs) are at increased risk of Clostridium difficile infection (CDI). We aimed to retrospectively describe the epidemiology of CDI in a national…